Phase II study of interferon-y versus interleukin-2 and interferon-α2b in metastatic renal cell carcinoma

Journal of Urology

Volumn 155, Issue 2, 1996, Pages 455-458

  Lümmen, Gerd ^a   Goepel, Mark ^a   Möllhoff, Stefan ^a   Hinke, Axel ^a   Otto, Thomas ^a   Rübben, Herbert ^a  

^a UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

Author keywords

Carcinoma, renal cell; Interferons, interleukin 2; Neoplasm metastasis

Indexed keywords

ALPHA2B INTERFERON; GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; FATIGUE; FEMALE; FEVER; HUMAN; KIDNEY CARCINOMA; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; CARCINOMA, RENAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON ALFA-2B; INTERFERON TYPE II; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL RATE;

EID: 0030038555     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)66417-6     Document Type: Article

References (20)

1. Choudhury, M., Efros, M. and Mittelman, A.: Interferons and interleukins in metastatic renal cell carcinoma. Urology, suppl, 41: 67, 1993.
2. Thrasher, J. B. and Paulson, D. F.: Prognostic factors in renal cancer. Urol. Clin. N. Amer., 20: 247, 1993.
3. Goepel, M. and Rübben, H.: Adjuvant therapy in renal cancer. World J. Urol., 9: 232, 1991.
4. Oliver, R. T. D., Nethersell, A. B. W. and Bottomley, J. M.: Unexplained spontaneous regression and α-interferon as treatment for metastatic renal carcinoma. Brit. J. Urol., 63: 128, 1989.
5. Rosenberg, S. A., Lotze, M. T., Yang, J. C., Linehan, W. M., Seipp, C., Calabro, S., Karp, S. E., Sherry, R. M., Steinberg, S. and White, D. E.: Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J. Clin. Oncol., 7: 1863, 1989.
6. Kirchner, H., de Riese, W., Allhoff, E., Poliwoda, H. and Atzpodien, J.: Immunotherapy of advanced renal cell cancer using subcutaneous recombinant interleukin-2 and interferon-α. World J. Urol., 9: 219, 1991.
7. Budd, G. T., Murthy, S., Finke, J., Sergi, J., Gibson, V., Medendorp, S., Barna, B., Boyett, J. and Bukowski, R. M.: Phase I trial of high dose bolus interleukin-2 and interferon alpha-2a in patients with metastatic malignancy. J. Clin. Oncol., 10: 804, 1992.
8. Markowitz, A., Talpaz, M., Lee, K., Parkinson, D., Doig, R., Rothberg, J., Levitt, D. and Gutterman, J.: Phase I-II study of recombinant interleukin-2 plus recombinant interferon-α2A in renal cell carcinoma. Proc. Amer. Soc. Clin. Oncol., 8: 146, abstract 568, 1989.
9. Quesada, J. R., Kurzrock, R., Sherwin, S. A. and Guttermann, J. U.: Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma. J. Biol. Resp. Mod., 6: 20, 1987.
10. Rinehart, J. J., Young, D., Laforge, J., Colburn, D. and Neidhart, J.: Phase I/II trial of recombinant gamma-interferon in patients with renal cell carcinoma: immunologic and biologic effects. J. Biol. Resp, Mod., 6: 302, 1987.
11. Garnick, M. B., Reich, S. D., Maxwell, B., Coval-Goldsmith, S., Richie, J. P. and Rudnick, S. A.: Phase I/II study of recombinant interferon gamma in advanced renal cell carcinoma. J. Urol., 139: 251, 1988.
12. Aulitzky, W., Gastl, G., Aulitzky, W. E., Herold, M., Kemmler, J., Mull, B., Frick, J. and Huber, C.: Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma. J. Clin. Oncol., 7: 1875, 1989.
13. Peto, R. and Peto, J.: Asymptomatically efficient rank invariant test procedures. J. Roy. Stat. Soc., part 2, A135: 185, 1972.
14. Mittelman, A., Puccio, C., Ahmed, T., Zeffren, J., Choudhury, A. and Arlin, Z.: A phase II trial of interleukin-2 by continuous infusion and interferon by intramuscular injection in patients with renal cell carcinoma. Cancer, 68: 1699, 1991.
15. Fossa, S. D., Aune, H., Baggerud, E., Granerud, T., Heilo, A. and Theodorsen, L.: Continuous intravenous interleukin-2 infusion and subcutaneous interferon-alpha in metastatic renal cell carcinoma. Eur. J. Cancer, 29A: 1313, 1993.
16. Atzpodien, J., Poliwoda, H. and Kirchner, H.: Alpha-interferon and interleukin-2 in renal cell carcinoma: studies in nonhospitalized patients. Sem. Oncol., suppl. 7, 18: 108, 1991.
17. Figlin, R. A., Belldegrun, A., Maldower, N., Zeffren, J. and deKernion, J.: Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A: an active outpatient regimen in metastatic renal cell carcinoma. J. Clin. Oncol., 10: 414, 1992.
18. Aulitzky, W. E., Aulitzky, W., Gastl, G., Lanske, B., Reitter, J., Frick, J., Tilg, H., Berger, H., Herold, M. and Huber, C.: Acute effects of single doses of recombinant interferon-gamma on blood cell counts and lymphocyte subsets in patients with advanced renal cell cancer. J. Interferon Res., 9: 425, 1989.
19. Ellerhorst, J. A., Kilbourn, R. J., Amato, R. J., Zukiwski, A. A., Jones, E. and Logothetis, C. J.: Phase II trial of low dose γ-interferon in metastatic renal cell carcinoma. J. Urol., 152: 841, 1994.
20. Atzpodien, J., Kirchner, H., Hänninen, E. L., Deckert, M., Fenner, M. and Poliwoda, H.: Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur. J. Cancer, suppl. 5, 29A: S6, 1993.